1. Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective
- Author
-
Nag Shona, Chatterjee Sanjoy, Swarup Binay, RR Rao, Kukreja Anil, Aggarwal Shyam, Nigade Jagdish, Bhattacharya Priyanka, Prasad Krishna, Warrier Arun, Patil Poonam, Suresh H. Advani, BK Smruti, Singh Randeep, Singhal Manish, Raju Titus Chacko, SS Alurkar, TP Sahoo, Srinivasan Sankar, Keechilat Pavithran, Singh Ashish, Rajendranath Rejiv, Goswami Chanchal, Agarwal Amit, Agarwal Vijay, Desai Chirag, and Gupta Sudeep
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,Lapatinib ,Targeted therapy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Breast cancer ,Trastuzumab ,Internal medicine ,medicine ,030212 general & internal medicine ,skin and connective tissue diseases ,education ,neoplasms ,education.field_of_study ,business.industry ,medicine.disease ,Metastatic breast cancer ,chemistry ,Trastuzumab emtansine ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Pertuzumab ,business ,medicine.drug - Abstract
Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.
- Published
- 2018